Physician profile
Summer D Moon
NPI 1457765968
$59,309.15
in general payments reported to CMS, 2019-2025
41 companies · $7,292 in 2025
The $7,292 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,005 · 2020: $5,343 · 2021: $5,668 · 2022: $7,988 · 2023: $29K · 2024: $2,220 · 2025: $7,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $6,419 · Consulting Fee: $2,475 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,300.00 |
| Food and Beverage | $6,418.80 |
| Consulting Fee | $2,475.00 |
| Education | $111.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $45,513.14 | 2019-2025 | Aklief, Twyneo, Epsolay |
| Arcutis Biotherapeutics, INC. | $3,718.16 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $1,015.69 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Mayne Pharma Commercial LLC | $1,002.81 | 2019-2025 | |
| Abbvie INC. | $722.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $694.03 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $648.16 | 2019-2024 | Siliq, Jublia, Targretin |
| Janssen Biotech, INC. | $577.92 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Leo Pharma INC. | $576.11 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $459.62 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $402.55 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Amgen INC. | $396.84 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $381.55 | 2019-2023 | |
| Ucb, INC. | $350.97 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $320.66 | 2022-2025 | Sotyktu |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $264.19 | 2020-2025 | |
| Incyte Corporation | $262.94 | 2021-2025 | Opzelura |
| Organogenesis INC. | $249.48 | 2021-2025 | Puraply, Novachor |
| Encore Dermatology INC. | $222.00 | 2019-2020 | |
| Dermira, INC. | $201.49 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $195.77 | 2020-2021 | |
| Journey Medical Corporation | $166.21 | 2019-2025 | |
| Almirall LLC | $138.66 | 2019-2023 | Seysara |
| Biofrontera INC. | $114.01 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Dermavant Sciences, INC. | $87.94 | 2022-2024 | Vtama |
| Dusa Pharmaceuticals, INC. | $80.04 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $58.55 | 2020-2023 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.98 | 2022-2024 | Spevigo |
| Strata Skin Sciences, INC. | $47.23 | 2021-2025 | Xtrac |
| Hill Dermaceuticals, INC. | $42.00 | 2024 | Tolak |
| Promius Pharma LLC | $39.90 | 2019 | |
| Aclaris Therapeutics, INC. | $38.18 | 2019 | |
| Celgene Corporation | $32.60 | 2019 | |
| Organon LLC | $32.33 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $23.74 | 2024 | Ycanth |
| Merz North America, INC. | $19.08 | 2019 | |
| Botanix Sb INC | $18.05 | 2025 | Sofdra |
| Csl Behring | $17.74 | 2019 | |
| Abbott Laboratories | $16.80 | 2022 | |
| Genentech USA, INC. | $15.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.